KR101441725B1 - 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제 - Google Patents

알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제 Download PDF

Info

Publication number
KR101441725B1
KR101441725B1 KR1020097026651A KR20097026651A KR101441725B1 KR 101441725 B1 KR101441725 B1 KR 101441725B1 KR 1020097026651 A KR1020097026651 A KR 1020097026651A KR 20097026651 A KR20097026651 A KR 20097026651A KR 101441725 B1 KR101441725 B1 KR 101441725B1
Authority
KR
South Korea
Prior art keywords
donepezil
disease
alzheimer
salt
carbostyril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097026651A
Other languages
English (en)
Korean (ko)
Other versions
KR20100020482A (ko
Inventor
헤이 아라이
Original Assignee
오츠카 세이야쿠 가부시키가이샤
각코호진 준텐도
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오츠카 세이야쿠 가부시키가이샤, 각코호진 준텐도 filed Critical 오츠카 세이야쿠 가부시키가이샤
Publication of KR20100020482A publication Critical patent/KR20100020482A/ko
Application granted granted Critical
Publication of KR101441725B1 publication Critical patent/KR101441725B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097026651A 2007-05-22 2008-05-21 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제 Expired - Fee Related KR101441725B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007135367 2007-05-22
JPJP-P-2007-135367 2007-05-22
PCT/JP2008/059763 WO2008143361A1 (en) 2007-05-22 2008-05-21 A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
KR20100020482A KR20100020482A (ko) 2010-02-22
KR101441725B1 true KR101441725B1 (ko) 2014-09-18

Family

ID=39636992

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097026651A Expired - Fee Related KR101441725B1 (ko) 2007-05-22 2008-05-21 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제

Country Status (27)

Country Link
US (1) US20100298375A1 (enExample)
EP (2) EP2157973B1 (enExample)
JP (1) JP5153870B2 (enExample)
KR (1) KR101441725B1 (enExample)
CN (1) CN101754758B (enExample)
AR (1) AR066664A1 (enExample)
AU (1) AU2008253977B2 (enExample)
BR (1) BRPI0811919A2 (enExample)
CA (1) CA2687289C (enExample)
CO (1) CO6251249A2 (enExample)
CY (1) CY1116683T1 (enExample)
DK (1) DK2157973T3 (enExample)
ES (1) ES2545959T3 (enExample)
HR (1) HRP20150843T1 (enExample)
HU (1) HUE025902T2 (enExample)
IL (1) IL202053A (enExample)
MX (1) MX2009012583A (enExample)
MY (1) MY146407A (enExample)
NZ (1) NZ581099A (enExample)
PL (1) PL2157973T3 (enExample)
PT (1) PT2157973E (enExample)
RU (1) RU2469723C2 (enExample)
SI (1) SI2157973T1 (enExample)
TW (2) TWI423802B (enExample)
UA (1) UA96633C2 (enExample)
WO (1) WO2008143361A1 (enExample)
ZA (1) ZA200908202B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
ES2665569T3 (es) 2011-03-01 2018-04-26 Pharnext Tratamiento de la isquemia cerebral
RU2015101100A (ru) * 2012-06-15 2016-08-10 Фаундейшн Фор Байомедикал Рисерч Энд Инновейшн Профилактическое и/или терапевтическое средство для умеренного когнитивного нарушения
US20160331922A1 (en) * 2013-12-23 2016-11-17 John W. Holaday Disposable container for air hydration
EP3459545A4 (en) 2016-05-19 2020-02-26 National Cerebral and Cardiovascular Center MEDICATION FOR PREVENTING AND / OR TREATING DEMENTIA
CN111032038A (zh) 2017-05-24 2020-04-17 H.隆德贝克有限公司 用于治疗阿尔茨海默氏病的药物组合
CN107602523B (zh) * 2017-09-11 2020-08-18 安徽中医药大学 京尼平类似物、制备方法及其应用
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229913A1 (en) 2002-12-13 2004-11-18 Eisal Co., Ltd. Therapeutic agent for severe Alzheimer's dementia

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JP2574099B2 (ja) 1992-05-21 1997-01-22 大塚製薬株式会社 アレルギー疾患治療剤
JPH10175864A (ja) 1996-12-16 1998-06-30 Otsuka Pharmaceut Co Ltd 慢性閉塞性肺疾患治療剤
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
ES2237078T3 (es) * 1998-01-16 2005-07-16 Eisai Co., Ltd. Procedimiento para producir derivados de donepezilo.
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
IL150509A (en) * 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229913A1 (en) 2002-12-13 2004-11-18 Eisal Co., Ltd. Therapeutic agent for severe Alzheimer's dementia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brain Research. Vol. 1185, pp.246-255 (2007.11.28.) *

Also Published As

Publication number Publication date
AU2008253977B2 (en) 2013-08-22
ZA200908202B (en) 2010-07-28
MX2009012583A (es) 2010-03-08
HRP20150843T1 (hr) 2015-09-11
KR20100020482A (ko) 2010-02-22
EP2937085A1 (en) 2015-10-28
US20100298375A1 (en) 2010-11-25
CA2687289C (en) 2015-09-15
TWI423802B (zh) 2014-01-21
RU2469723C2 (ru) 2012-12-20
WO2008143361A1 (en) 2008-11-27
AU2008253977A1 (en) 2008-11-27
TWI489983B (zh) 2015-07-01
NZ581099A (en) 2012-03-30
RU2009147456A (ru) 2011-06-27
AR066664A1 (es) 2009-09-02
EP2157973B1 (en) 2015-07-15
TW200904428A (en) 2009-02-01
JP5153870B2 (ja) 2013-02-27
EP2937085B1 (en) 2019-07-10
CN101754758A (zh) 2010-06-23
PT2157973E (pt) 2015-10-14
IL202053A (en) 2016-04-21
EP2157973A1 (en) 2010-03-03
CO6251249A2 (es) 2011-02-21
BRPI0811919A2 (pt) 2014-11-18
DK2157973T3 (en) 2015-08-17
SI2157973T1 (sl) 2015-10-30
IL202053A0 (en) 2010-06-16
UA96633C2 (uk) 2011-11-25
MY146407A (en) 2012-08-15
TW201412315A (zh) 2014-04-01
CN101754758B (zh) 2012-10-24
PL2157973T3 (pl) 2015-12-31
CA2687289A1 (en) 2008-11-27
CY1116683T1 (el) 2017-03-15
HUE025902T2 (en) 2016-05-30
HK1140422A1 (en) 2010-10-15
ES2545959T3 (es) 2015-09-17
JP2010527993A (ja) 2010-08-19
HK1215384A1 (en) 2016-08-26

Similar Documents

Publication Publication Date Title
KR101441725B1 (ko) 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제
JP2014185161A (ja) シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤
JP2003520237A (ja) 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤
JP4063341B2 (ja) 緑内障治療剤及び眼圧降下剤
WO2023123468A1 (zh) 心脑血管药物及其应用
EP1437137B1 (en) Drugs comprising combination of antithrombotic agent with pyrazolone derivative
US20150258077A1 (en) Substituted benztropine analogs for treatment of dementia
HK1215384B (en) A medicament comprising a carbostyril derivative and donezepil for treating alzheimer's disease
HK1140422B (en) A medicament comprising a carbostyril derivative and donepezil for treating alzheimer's disease
HK1213494A1 (en) Combination therapies for the treatment of alzheimer's disease and related disorders
HK1213494B (en) Combination therapies for the treatment of alzheimer's disease and related disorders
JPWO1998008831A1 (ja) アルツハイマー病予防・治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180816

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210912

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210912